Itraconazole is a new orally active triazole antifungal agent with enhanced activity against Candida species. In the clinical trial described in this paper, we compared the efficacy and safety of itraconazole capsules with those of clotrimazole vaginal tablets and placebo oral capsules for women with acute vulvovaginal candidiasis. Ninety-five patients were randomized in a 2:1:1 fashion to 
30%1), but this difference did not reach statistical significance (P > 0.05; 1 = 0.81). Mycological response rates for itraconazole and clotrimazole were also similar. No patients enrolled in this study discontinued treatment because of an adverse event. Minor side effects were reported by 35, 4, and 41% of patients who received itraconazole, clotrimazole, and placebo, respectively. The most common side effects associated with itraconazole therapy were nausea and headache. In summary, itraconazole was found to be as effective and safe as clotrimazole in women with acute candida vaginitis. Moreover, oral therapy was highly favored over intravaginal treatment in our survey of patients.
The introduction of potent imidazole and triazole antifungal agents has significantly altered the duration of treatment of acute vaginal candidiasis (16) . Short courses of therapy with various topical formulations are highly effective and produce few adverse effects (7, 26, 31) . Oral agents, such as fluconazole, are also well tolerated and are as effective as local treatments (19, 25) . Moreover, patients with candida vaginitis express a strong preference for oral therapy (1, 29) .
Itraconazole is a new orally active triazole antifungal drug (21) . This agent appears to be an attractive alternative for the treatment of vaginal candidiasis because of its enhanced activity against Candida species and its low incidence of untoward effects (8) . In an experimental model of candidal vaginitis, itraconazole was shown to be more efficacious than ketoconazole in eradicating vaginal infection with Candida albicans (24) .
In patients treated prior to hysterectomy, itraconazole was found to be detectable in vaginal tissue by 1 h after a 200-mg oral dose and tissue itraconazole concentrations above the MIC for Candida species were maintained for at least 15 h (11). On the basis of these findings, various dosage regimens of itraconazole in open studies of women with acute vaginal candidiasis were investigated (2, 4, 22) . The overall data suggest that the best clinical and mycologic results would be obtained with 200 mg of itraconazole once daily for 3 days (6) .
The clinical trial that we describe was designed to compare the efficacy and safety of a 3-day course of itraconazole with those of clotrimazole and placebo treatment Of the 35 itraconazole-treated patients evaluated up to 4 weeks posttreatment, 27 (83%) remained asymptomatic or had improved (Table 2 ). In the clotrimazole-treated group, only 12 (67%) of 18 patients were still clinically cured or had improved. The attrition rate was high for those women who received placebo. Of the seven patients that remained in the study, four (57%) were still asymptomatic and three (43%) were clinical failures. Clinical responses among treatment groups were not statistically different at the second visit. The mycological response at the 4-week posttreatment visit was (16) . Local applications of these antifungal preparations are usually without untoward effects, but most patients still prefer oral therapy (17) . Ketoconazole is an effective oral agent, but it has not been widely utilized for the treatment of candida vaginitis because of the higher risk of systemic toxicity.
A new class of azole antifungal agents, the triazoles, has recently been introduced into clinical practice. These drugs appear to offer both microbiological and clinical advantages over the imidazoles. Terconazole, the prototype agent, exhibits potent in vitro activity against C. albicans as well as other Candida species (28, 30) . In addition, terconazole has also been shown to be more effective than imidazoles in the treatment of vaginal candidiasis in rats (30) . In clinical trials, various topical preparations of terconazole achieve cure rates equal or superior to those with imidazole antifungal agents (31) . The increased incidence of non-C. albicans species causing vaginal candidiasis may become an important impetus for the use of triazoles (9) . However, data assessing the efficacy of terconazole versus imidazoles in women infected with non-C. albicans species are lacking.
The oral triazoles (fluconazole and itraconazole) may ultimately become the treatment of choice for women with vaginal candidiasis (18) . Unlike terconazole, these systemically active triazoles have the capability to eliminate rectal carriage of Candida species, which may be an important determinant in the relapse or recurrence of vulvovaginal candidiasis (10, 15) . In contrast to ketoconazole, these agents are highly effective following short courses of therapy and produce minimal side effects (6, 17, 19, 25) . The oral triazoles do not appear to alter vaginal flora and may prove advantageous in the treatment of non-C. albicans species (3, 5) . Furthermore, patient acceptance of this form of therapy has been highly favorable (1, 29) .
Numerous studies comparing newer antifungal agents in the treatment of vulvovaginal candidiasis have been published. Mycological cure rates for the various azole derivatives range from 50 to 100% when assessed within 15 days of completion of treatment (16) . The mycological cure rates observed in the present study were similar to those of other clinical trials of azole antifungal agents used in the treatment of vulvovaginal candidiasis and were comparable to those from a previous study that we conducted with this patient population (26) . It was not surprising to discover that approximately one-third of our patients who received placebo capsules had cultures that were negative for Candida species 1 week following treatment. Similar findings have also been observed in clinical trials with placebo suppositories (31) and placebo oral capsules (23) .
Virtually all of our patients treated with active medication showed significant improvements in their signs and symptoms. In contrast, almost one-quarter of the patients who received the placebo were initial clinical failures. Moreover, most of the patients who exhibited initial improvement with the placebo relapsed and required antifungal therapy. Our overall clinical failure rate with itraconazole was less than that observed with clotrimazole (17 versus 30%), but this difference did not reach statistical significance. It is important to note that because of our small sample size, the power (1 -P) of finding a statistical difference between active treatment regimens would be approximately 0.2. This suggests that a large type II error for detecting a difference between these two drugs exists.
Disparate findings in multicenter trials comparing fluconazole to topical antifungal therapy have been reported. In one study (19) , the long-term clinical response rate (27 to 62 days after treatment) was found to be significantly greater following a single 150-mg dose of fluconazole than with clotrimazole (P = 0.02). In another trial (25) , the clinical response rates 30 to 35 days posttreatment were similar following a 3-day treatment regimen of fluconazole or clotrimazole. Treatment with a single 150-mg dose of fluconazole resulted in a relapse rate 80 to 100 days after therapy similar to that of treatment with a 150-mg intravaginal tablet of econazole (17) . Additional clinical trials with larger sample sizes would be of interest to help determine whether systemic therapy with these newer triazoles does indeed lead to fewer clinical relapses.
A course of treatment with an intravaginal preparation of an azole antifungal drug is usually without major adverse effects. Minor side effects, such as burning, irritation, itching, and dyspareunia, can occur with all topical agents (13) . The frequency and severity of side effects depends on many factors, including dose, duration of therapy, and individual susceptibility (12, 26) . In the present investigation, only one patient treated with clotrimazole reported an untoward effect. In contrast, over one-third of our patients who received itraconazole reported an adverse experience. More importantly, none of these side effects were severe and no patient discontinued therapy. Of note, a similar incidence and spectrum of adverse effects were reported by our patients VOL. 37, 1993 on August 14, 2017 by guest http://aac.asm.org/ ANTIMICROB. AGENTS CHEMOTHER. who received placebo capsules. We feel that this investigation further substantiates the relative safety of itraconazole for the treatment of vaginal candidiasis that has been observed in placebo-controlled (23) and open studies (2, 22) .
In summary, itraconazole was found to be as effective as clotrimazole for the treatment of acute vulvovaginal candidiasis. Although more minor side effects were reported with itraconazole use, no patient discontinued therapy. Itraconazole therapy was highly favored over therapy with clotrimazole in our survey of patients. This finding has also been documented in a similar opinion survey (27) . This suggests that this mode of therapy may help overcome the poor drug compliance observed in patients treated for vulvovaginal candidiasis (14) .
